Matrix metalloproteinases in patients with myocardial infarction and percutaneous revascularization.
BACKGROUND
Extracellular matrix remodeling is a component of coronary artery disease (CAD). Matrix metalloproteinases (MMPs) are enzymes involved in extracellular matrix degradation. The extrapolation of the role MMPs play in the clinical setting of acute coronary syndromes has not yet been defined.


METHODS
Samples from 100 subjects undergoing cardiac catheterization were analyzed for serum levels of MMP-1, MMP-2, and MMP-9. These markers were assessed before, immediately after, and 24 hours after cardiac catheterization. Relationships among MMP levels, baseline characteristics, angiography findings and clinical course were assessed.


RESULTS
Comparing subjects with myocardial infarction versus those without, baseline MMP-1 levels were not different at baseline but increased during the hospital stay, MMP-2 levels were higher at baseline and throughout the monitoring period and MMP-9 levels lower and decreased over time. MMP-1 was higher 24 hours after catheterization in subjects undergoing revascularization. Subjects undergoing percutaneous revascularization had higher MMP-9 levels following revascularization than those subjects undergoing angiography without angioplasty.


CONCLUSIONS
Serial monitoring of MMPs indicates a differential subtype response to myocardial infarction and percutaneous revascularization. Results of this study indicate that MMP subtypes may play differing roles in the manifestation of acute coronary syndromes and response to revascularization.
Cardiology Service (ATTN: MCHE-MDC), Brooke Army Medical Center, 3851 Roger Brooke Drive, Fort Sam Houston, San Antonio, TX 78234-6200, USA. Robert.Eckart@amedd.army.mil
Robert E
RE
Eckart
Catherine F T
CF
Uyehara
Eric A
EA
Shry
James L
JL
Furgerson
Richard A
RA
Krasuski
D000328:Adult; D000368:Aged; D015906:Angioplasty, Balloon, Coronary; D015415:Biomarkers / Q000097:blood; D006328:Cardiac Catheterization; D003324:Coronary Artery Disease / Q000201:enzymology / Q000628:therapy; D003326:Coronary Circulation / Q000502:physiology; D005260:Female; D006801:Humans; D008297:Male; D020781:Matrix Metalloproteinase 1 / Q000097:blood; D020778:Matrix Metalloproteinase 2 / Q000097:blood; D020780:Matrix Metalloproteinase 9 / Q000097:blood; D020782:Matrix Metalloproteinases / Q000097:blood*; D008875:Middle Aged; D009203:Myocardial Infarction / Q000201:enzymology* / Q000628:therapy*; D009206:Myocardium / Q000378:metabolism / Q000473:pathology; D009336:Necrosis; D011446:Prospective Studies; D013997:Time Factors; D016896:Treatment Outcome
D015415:Biomarkers; D020782:Matrix Metalloproteinases; D020778:Matrix Metalloproteinase 2; D020780:Matrix Metalloproteinase 9; D020781:Matrix Metalloproteinase 1